Mariner
NVO

Mariner’s Novo Nordisk NVO Stock Holding History

Mariner’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.1M Buy
330,742
+8,509
+3% +$403K 0.01% 658
2025
Q4 		$16.4M Sell
322,233
-22,496
-7% -$1.15M 0.02% 508
2025
Q3 		$19.1M Sell
344,729
-33,938
-9% -$1.99M 0.02% 429
2025
Q2 		$26.1M Buy
378,667
+7,406
+2% +$504K 0.04% 350
2025
Q1 		$25.8M Buy
371,261
+7,948
+2% +$656K 0.04% 329
2024
Q4 		$31.3M Buy
363,313
+16,634
+5% +$1.8M 0.05% 279
2024
Q3 		$41.3M Buy
346,679
+3,322
+1% +$443K 0.07% 237
2024
Q2 		$49M Buy
343,357
+28,989
+9% +$3.84M 0.1% 192
2024
Q1 		$40.4M Buy
314,368
+17,245
+6% +$2.05M 0.08% 218
2023
Q4 		$30.7M Buy
297,123
+15,014
+5% +$1.48M 0.07% 226
2023
Q3 		$25.7M Buy
282,109
+27,065
+11% +$2.38M 0.07% 247
2023
Q2 		$20.6M Sell
255,044
-3,720
-1% -$304K 0.06% 279
2023
Q1 		$20.6M Sell
258,764
-11,918
-4% -$845K 0.06% 277
2022
Q4 		$18.3M Buy
270,682
+6,612
+3% +$388K 0.06% 290
2022
Q3 		$13.2M Buy
264,070
+66,650
+34% +$3.57M 0.05% 299
2022
Q2 		$11M Sell
197,420
-29,352
-13% -$1.63M 0.05% 309
2022
Q1 		$12.6M Buy
226,772
+6,144
+3% +$315K 0.05% 311
2021
Q4 		$12.4M Buy
220,628
+81,126
+58% +$4.39M 0.05% 278
2021
Q3 		$6.7M Sell
139,502
-15,808
-10% -$764K 0.04% 319
2021
Q2 		$6.5M Sell
155,310
-390
-0.3% -$15.1K 0.04% 292
2021
Q1 		$5.25M Sell
155,700
-16,632
-10% -$592K 0.04% 301
2020
Q4 		$6.02M Buy
172,332
+67,726
+65% +$2.34M 0.05% 265
2020
Q3 		$3.63M Buy
104,606
+1,094
+1% +$36.5K 0.03% 295
2020
Q2 		$3.39M Buy
103,512
+18,756
+22% +$599K 0.03% 308
2020
Q1 		$2.55M Buy
84,756
+9,602
+13% +$286K 0.03% 326
2019
Q4 		$2.17M Buy
75,154
+1,792
+2% +$49.6K 0.02% 380
2019
Q3 		$1.9M Buy
73,362
+2,984
+4% +$75.5K 0.02% 371
2019
Q2 		$1.8M Buy
70,378
+2,842
+4% +$70.2K 0.02% 407
2019
Q1 		$1.77M Buy
67,536
+2,216
+3% +$54.5K 0.03% 397
2018
Q4 		$1.5M Buy
65,320
+6,684
+11% +$149K 0.03% 366
2018
Q3 		$1.38M Buy
58,636
+144
+0.2% +$3.51K 0.04% 350
2018
Q2 		$1.35M Buy
58,492
+23,492
+67% +$558K 0.04% 336
2018
Q1 		$862K Sell
35,000
-28,898
-45% -$759K 0.03% 341
2017
Q4 		$1.71M Sell
63,898
-1,316
-2% -$33.5K 0.07% 224
2017
Q3 		$1.57M Sell
65,214
-3,206
-5% -$72.4K 0.07% 204
2017
Q2 		$1.47M Buy
68,420
+3,246
+5% +$65.5K 0.07% 204
2017
Q1 		$1.12M Buy
65,174
+10,428
+19% +$182K 0.05% 259
2016
Q4 		$982K Sell
54,746
-3,290
-6% -$59.6K 0.05% 273
2016
Q3 		$1.21M Buy
58,036
+9,772
+20% +$242K 0.06% 245
2016
Q2 		$1.3M Sell
48,264
-13,448
-22% -$369K 0.07% 221
2016
Q1 		$1.67M Sell
61,712
-3,208
-5% -$85.9K 0.1% 181
2015
Q4 		$1.89M Buy
64,920
+50,440
+348% +$1.4M 0.12% 149
2015
Q3 		$393K Buy
+14,480
New +$410K 0.02% 363
2013
Q4 		– Sell
-14,510
Closed -$246K – 350
2013
Q3 		$246K Sell
14,510
-270
-2% -$4.54K 0.05% 261
2013
Q2 		$229K Buy
+14,780
New +$246K 0.05% 237

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Mariner's NVO Position: Q1 2026 in Review

Mariner increased its Novo Nordisk (NVO) stake by 2.6% in Q1 2026, buying an estimated $403K and bringing the position to 330,742 shares worth $12.1M. The position accounts for 0.01% of the portfolio, ranked #658.

Mariner first reported a position in NVO in Q2 2013 and has held it in 45 quarters since. The position peaked at $49M in Q2 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Mariner held 330,742 shares of Novo Nordisk worth $12.1M as of Q1 2026.
  • Mariner bought 8,509 Novo Nordisk shares in Q1 2026, an estimated $403K.
  • Novo Nordisk made up 0.01% of Mariner's portfolio in Q1 2026, its #658 holding.
  • Mariner first reported a position in Novo Nordisk in Q2 2013 and has held it in 45 quarters since.
  • Mariner's Novo Nordisk position peaked at $49M in Q2 2024.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.